Skip to content
Gujarat Themis Biosyn logo

Gujarat Themis Biosyn

GUJTHEM NSE
₹387.75 +10.60 (+2.81%)
P/E
86.74
View as Markdown
MCP
Close 4 Nov 2026 ₹387.75 −61.65 −13.7% 1Y
Start ₹449.40

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
18.10%
Debt to Equity
0.56
EPS (TTM)
₹4.47
Book Value
₹58.18
Market Cap
—
P/E (TTM)
86.74
P/B
6.66
ROE
17.40%
Dividend Yield
0.18%
EBITDA
₹78.00 Cr
52W High
₹470.05
52W Low
₹225.05
Day Range
₹373.85 – ₹397.00
Volume
1,07,191

Peer Comparison

Healthcare › Pharmaceuticals

Gujarat Themis Biosyn peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Gujarat Themis Biosyn (this company)
₹387.7586.74₹4,924 Cr6.660.18%17.40%18.10%₹174 Cr₹48 Cr
Median 8 companies₹1,587.7058.71₹1,25,337 Cr5.720.44%16.95%17.95%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

Category scores

Quality
62
Good
Returns, margins, earnings quality 22% weight
Valuation
20
Poor
Cheap vs sector & own history 24% weight
Growth
64
Good
Sales & profit trajectory 9% weight
Financial Health
62
Good
Solvency, leverage, coverage 9% weight
Momentum
39
Weak
Trend strength, vol-adjusted 12% weight
Ownership
17
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.1%

Weaknesses

4
  • Stock is trading at 14.0 times its book value
  • Promoter holding has decreased over last quarter: -11.5%
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 89.3 to 134 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3511
OscillatorsNeutral252
Moving AveragesStrong Bullish109

Key readings

RSI (14)
55.11
Neutral
MACD (12,26,9)
−4.84
Bullish
SMA (50)
394.08
Bearish
SMA (200)
357.05
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+17.53%
5Y+12.78%
3Y+3.90%
1Y+9.93%
TTM+16.11%

Net profit

Net profit growth by window
10Y+25.12%
5Y+9.39%
3Y−6.77%
1Y−4.08%
TTM+6.67%

Operating cash flow

Operating cash flow growth by window
10Y+28.47%
5Y+34.82%
3Y+7.91%
1Y−46.15%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+27.60 pp
5Y+1.82 pp
3Y−4.22 pp
1Y+0.08 pp
TTM+4.45 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹36.00 Cr
Mar 2018₹39.00 Cr
Mar 2019₹41.00 Cr
Mar 2020₹85.00 Cr
Mar 2021₹91.00 Cr
Mar 2022₹115 Cr
Mar 2023₹148 Cr
Mar 2024₹170 Cr
Mar 2025₹151 Cr
Mar 2026₹166 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹4.00 Cr
Mar 2018₹4.00 Cr
Mar 2019₹6.00 Cr
Mar 2020₹24.00 Cr
Mar 2021₹30.00 Cr
Mar 2022₹44.00 Cr
Mar 2023₹58.00 Cr
Mar 2024₹59.00 Cr
Mar 2025₹49.00 Cr
Mar 2026₹47.00 Cr

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Gujarat Themis Biosyn Ltd is a healthcare company with a market cap of ₹4,214 Cr trading at a PE of 90.3x and 14.6x book value. The company has delivered strong long-term stock CAGR of 48% over 10 years but recent profit growth has turned negative at -4% TTM, while ROE has moderated from a 5-year average of 29% to 17% in the last year.

Bull Case 7
  • Strong long-term wealth creation with stock CAGR of 48% over 10 years and 55% over 5 years
  • Robust long-term ROE track record of 32% over 10 years and 29% over 5 years, indicating efficient capital deployment
  • Compounded sales growth of 18% over 10 years demonstrates sustained revenue expansion
  • Compounded profit growth of 26% over 10 years reflects strong long-term earnings trajectory
  • TTM sales growth of 10% shows continued top-line momentum despite profit pressures
  • 5-year compounded profit growth of 9% remains positive despite recent deceleration
  • 3-year ROE of 23.1% remains well above cost of equity for most Indian companies
Bear Case 7
  • TTM profit growth has turned negative at -4%, signaling earnings deterioration
  • 3-year compounded profit decline of -7% indicates a sustained earnings downtrend
  • Price-to-book of 14.6x is very high, implying significant premium to asset value
  • Debtor days have increased from 89.3 to 134 days, suggesting deteriorating working capital efficiency and potential collection issues
  • Promoter holding has decreased by 4.13% over the last 3 years, which may signal reduced insider confidence
  • ROE has declined sharply from 29% (5-year average) to 17% in the last year, a 12 percentage point drop
  • Company might be capitalizing interest costs, which could overstate reported profits and asset values

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Gujarat Themis Biosyn is in active expansion mode with two acquisitions (MicroBiopharm Japan, Sanofi portfolio), international subsidiary setup in Ireland, and potential fundraising underway. Key risks include a ₹90.38 crore arbitration dispute with a supplier and indirect encumbrance on promoter shares. The growth trajectory is improving with strategic moves into new geographies and product portfolios, though execution and funding clarity remain near-term watchpoints.

Headwinds 2
  • Arbitration claim filed Jun 26

    Gujarat Themis Biosyn initiated arbitration against Optimus Drugs claiming ₹90.38 crore for breach of supply agreement, indicating a disrupted supplier relationship.

  • Indirect share encumbrance disclosed Jul 2

    CTL Trusteeship disclosed an indirect encumbrance over Gujarat Themis Biosyn shares due to pledges by Vividhmargi Investments, signaling promoter-level leverage risk.

Positives 3
  • Acquisitions fuel growth strategy Jun 29

    Company reported FY26 revenue of ₹16,582.28 lakh and announced acquisitions of MicroBiopharm Japan and Sanofi's select product portfolio to expand capabilities.

  • Ireland subsidiary incorporated Jun 17

    Step-down subsidiary Themis Biosyn Private Limited incorporated in Ireland on June 16, 2026, with €100 share capital, signaling international expansion intent.

  • Board evaluating fund raising Jun 16

    Board meeting scheduled for June 19, 2026 to evaluate raising funds via preferential issue and private placement of equity shares and debentures.

Neutral 1
  • Promoter inter-se share transfer Jun 24

    Sachin D. Patel will purchase up to 26 lakh shares from Themis Medicare Limited between June 30–July 3, 2026 at ₹400.45 per share, a promoter-level rebalancing.

Quarterly Results

₹ Cr
GUJTHEM quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
50
40
39
42
39
35
40
38
36
42
43
44
44
Expenses
26
23
21
21
20
19
21
22
22
21
22
25
23
Operating Profit
24
17
18
21
19
15
19
16
14
21
21
19
21
OPM %
47%
42%
46%
50%
48%
44%
48%
42%
39%
49%
49%
44%
48%
Other Income
1
1
1
1
1
0
0
1
0
1
0
1
0
Interest
0
0
0
0
0
0
0
0
0
0
1
2
2
Depreciation
1
1
1
1
1
1
2
1
2
3
4
4
4
PBT
24
17
18
21
18
14
17
16
12
19
17
14
15
Tax %
26%
26%
26%
24%
26%
26%
25%
25%
25%
24%
26%
24%
27%
Net Profit
18
13
13
16
13
11
13
12
9
14
12
11
11
EPS (₹)
1.63
1.15
1.19
1.46
1.21
0.97
1.19
1.1
0.83
1.31
1.14
1
1.02

Profit & Loss

₹ Cr
GUJTHEM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
31
33
36
39
41
85
91
115
148
170
151
166
174
Expenses
25
27
30
33
34
53
50
57
75
91
82
89
91
Operating Profit
7
6
6
6
7
32
40
58
74
79
69
76
82
OPM %
21%
19%
17%
16%
18%
37%
45%
51%
50%
46%
46%
46%
47%
Other Income
0
0
0
0
2
2
3
4
7
4
2
2
2
Interest
0
0
0
0
0
1
1
1
0
0
0
2.95
5
Depreciation
1
1
1
1
1
1
2
2
3
4
5
13
15
PBT
5
5
5
5
8
31
41
59
77
79
66
62
65
Tax %
0%
0%
10%
20%
22%
24%
26%
26%
25%
25%
26%
25%
—
Net Profit
5
5
4
4
6
24
30
44
58
59
49
47
49
EPS (₹)
0.42
0.42
0.4
0.36
0.59
2.17
2.77
4
5.32
5.43
4.48
4.28
4.47
Div. Payout %
0%
0%
0%
0%
0%
10%
0%
37%
14%
12%
15%
16%
—

Balance Sheet

₹ Cr
GUJTHEM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7
7
7
7
7
7
7
7
7
7
11
11
Reserves
−8
−3
1
5
11
35
63
96
142
194
237
277
Borrowings
6
3
4
1
6
8
5
1
0
3
30
162
Other Liabilities
9
8
9
8
8
14
14
18
17
17
22
54
Total Liabilities
15
15
21
20
33
64
88
122
166
221
301
503
Fixed Assets
10
9
11
11
15
17
19
19
33
38
41
289
CWIP
0
0
0
0
1
0
2
13
21
91
184
121
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
5
5
11
10
17
47
67
90
113
92
76
93
Total Assets
15
15
21
20
33
64
88
122
166
221
301
503

Cash Flow

₹ Cr
GUJTHEM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
3
4
3
6
1
1
11
40
39
64
91
49
Investing
0
−1
−3
−1
−6
−3
−2
−30
−20
−55
−112
−172
Financing
−3
−3
0
−4
5
2
−5
−14
−13
−9
26
115
Net Cash Flow
−1
0
0
1
0
0
3
−4
6
0
5
−9
Free Cash Flow
2
3
0
5
−5
−3
7
26
16
−10
−25
−124
CFO/OP
44
73
57
99
25
24
51
94
81
107
156
78

Ratios

GUJTHEM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
28
24
71
26
52
87
59
80
44
58
76
134
Inventory Days
—
—
—
78
—
194
144
255
201
33
75
263
Days Payable
—
—
—
947
—
240
84
145
131
99
218
625
Cash Conversion Cycle
28
24
71
−844
52
41
119
189
114
−7
−67
−228
Working Capital Days
−76
−70
−42
−43
−58
42
80
155
91
50
46
8
ROCE %
121%
81%
55%
42%
45%
84%
67%
67%
61%
45%
27%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Gujarat Themis Biosyn insights

71 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 59.33%
  • Public 16.54%
  • DIIs 12.65%
  • Others 7.68%
  • FIIs 3.80%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Gujarat Themis Biosyn

What does Gujarat Themis Biosyn Ltd do?
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process
Where is Gujarat Themis Biosyn Ltd (GUJTHEM) listed?
Gujarat Themis Biosyn Ltd trades as GUJTHEM on the NSE and under code 506879 on the BSE.
Which sector does Gujarat Themis Biosyn Ltd belong to?
Gujarat Themis Biosyn Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd trades at a PE ratio of 86.74 as of 4 Nov 2026, on earnings per share of ₹4.47, against a book value of ₹58.18 per share.
What is the 52-week high and low of Gujarat Themis Biosyn Ltd?
Over the last 52 weeks Gujarat Themis Biosyn Ltd has traded between ₹225.05 and ₹470.05 as of 4 Nov 2026.
Does Gujarat Themis Biosyn Ltd pay dividends?
Gujarat Themis Biosyn Ltd has a dividend yield of 0.18%.
What is the Return on Equity (ROE) of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd reported a return on equity of 17.40%. Its debt-to-equity ratio is 0.56.

Company Information

Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process

Website gtbl.in
CEO Dr. Sachin Dinesh Patel CChem., Ph.D.
Employees 221
Listed 25 Feb 2025
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GUJTHEM.md for Gujarat Themis Biosyn Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month